NDATOPICALSOLUTION
Approved
Nov 2009
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
5/8 — Partial
PENNSAID (diclofenac sodium) by Amgen is (ak) is unknown. First approved in 2009.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PENNSAID is a topical diclofenac sodium solution approved in 2009 for localized pain relief, leveraging the anti-inflammatory properties of a nonsteroidal anti-inflammatory drug (NSAID) delivered directly to affected tissues. The mechanism of action involves inhibition of cyclooxygenase enzymes at the application site. It is primarily used by patients seeking non-systemic pain management for conditions like osteoarthritis and musculoskeletal pain.
$135MPart D
Peak3.9 years to LOEThe product is at peak lifecycle with substantial Part D spending, indicating a mature, stable commercial operation requiring focus on market maintenance and operational efficiency.
Mechanism of Action
(AK) is unknown.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Efficacy of Diclofenac Sodium Shock Wave Phonophoresis on Patients With Subacromial Impingement Syndrome
Started Jun 2026
70 enrolled
Shock WaveSubacromial Impingement Syndrome
A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp
Started Oct 2022
447 enrolled
Keratosis, Actinic
To Evaluate the Superiority of Fixed Combination (Orfenadrine 35mg, Acetaminophen 325mg, Caffeine 65mg and Diclofenac Sodium 50mg) Compared to Voltaren® (Diclofenac Sodium 50mg) in the Treatment of Acute Postural Low Back Pain.
Started Jan 2021
110 enrolled
Postural Low Back PainMechanical Low Back Pain
A Bioequivalence Study Using Clinical Endpoint for Diclofenac Sodium Gel 1% in Osteoarthritis Knee"
Started May 2017
1,220 enrolled
Osteoarthritis, Knee
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp
Started Oct 2015
492 enrolled
Actinic Keratosis
Worked on PENNSAID at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.